Moderna's Flu Revolution: mRNA Vaccine Outperforms Conventional Shots

Moderna's mRNA flu vaccine shows greater efficacy than conventional shots in a large trial, boosting hope for mRNA technology in flu prevention. Now under FDA review, it's poised to be the first mRNA flu shot in the U.S. Approval might come with further studies in older populations.

In a groundbreaking late-stage international trial, Moderna's mRNA-based seasonal flu vaccine demonstrated superior efficacy compared to conventional flu shots. Researchers reported that the vaccine, tested on over 40,000 adults aged 50 and older, worked significantly better than existing options, with a 26.6% higher effectiveness than a standard-dose flu shot from GSK.

The U.S. Food and Drug Administration is currently reviewing Moderna's vaccine after initially rejecting it due to concerns over testing comparisons. If approved, Moderna's shot would become the first U.S. seasonal flu vaccine using mRNA technology, facing extra scrutiny from Health Secretary Robert F. Kennedy Jr., who has long criticized mRNA-based solutions.

Side effects reported from the Moderna vaccine, such as injection-site pain and fatigue, were mostly mild, with severe reactions comparable to standard vaccines. While the committee's concerns initially halted progress, ongoing regulatory reviews in the EU, Canada, and Australia, along with a conditional acceptance by the FDA for further study, could pave the way for this innovative approach in influenza prevention.